Drug Safety : Drug safety evaluation of naltrexone/bupropion for the treatment of obesity , Benefits versus risk profile of buparlisib for the treatment of breast cancer , Histone deacetylase inhibitors for the treatment of myeloma, Muscle and statins, Glucocorticoid-related adverse events in patients with rheumatoid arthritis, Safety of epidural drugs, Safety and tolerability of injectable lipid-lowering drugs, Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection, Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system,

 Update on drug safety evaluation of naltrexone/bupropion for the 
   treatment of obesity 
   Nicholas T. Bello 
   Pages: 549-552 
   DOI: 10.1080/14740338.2019.1618268 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1618268%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Benefits versus risk profile of buparlisib for the treatment of breast 
   cancer 
   Anne Patsouris, Paule Augereau, Jean-Sebastien Frenel, Marie Robert, 
   Carole Gourmelon, Emmanuelle Bourbouloux, Dominque Berton-Rigaud, 
   Louise-Marie Chevalier & Mario Campone 
   Pages: 553-562 
   DOI: 10.1080/14740338.2019.1623877 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1623877%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   A comparative safety review of histone deacetylase inhibitors for the 
   treatment of myeloma 
   Guldane Cengiz Seval & Meral Beksac 
   Pages: 563-571 
   DOI: 10.1080/14740338.2019.1615051 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1615051%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Muscle and statins: from toxicity to the nocebo effect 
   Juan Pedro-Botet, Elisenda Climent & David Benaiges 
   Pages: 573-579 
   DOI: 10.1080/14740338.2019.1615053 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1615053%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   An updated review of glucocorticoid-related adverse events in patients 
   with rheumatoid arthritis 
   Mariana Luís, João Freitas, Flávio Costa, Frank Buttgereit, Maarten 
   Boers, Da Silva JAP & Tânia Santiago 
   Pages: 581-590 
   DOI: 10.1080/14740338.2019.1615052 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1615052%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Safety of epidural drugs: a narrative review 
   ML van Zuylen, W ten Hoope, EME Bos, J Hermanides, MF Stevens & MW 
   Hollmann 
   Pages: 591-601 
   DOI: 10.1080/14740338.2019.1617271 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1617271%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Occurrence of hepatocellular carcinoma after direct-acting antiviral 
   therapy for hepatitis C virus infection: literature review and risk 
   analysis 
   Giovanni Galati, Moises Muley, Mauro Viganò, Massimo Iavarone, 
   Alessandro Vitale, Chiara Dell’Unto, Quirino Lai, Giuseppe Cabibbo, 
   Rodolfo Sacco, Erica Villa & Franco Trevisani 
   Pages: 603-610 
   DOI: 10.1080/14740338.2019.1617272 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1617272%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Safety and tolerability of injectable lipid-lowering drugs: an update 
   of clinical data 
   Larysa Strilchuck, Federica Fogacci & Arrigo Fg Cicero 
   Pages: 611-621 
   DOI: 10.1080/14740338.2019.1620730 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1620730%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT 

   Disproportionality analysis of bullous pemphigoid adverse events with 
   PD-1 inhibitors in the FDA adverse event reporting system 
   Pushkar Aggarwal 
   Pages: 623-633 
   DOI: 10.1080/14740338.2019.1619693 
   https://www.tandfonline.com/action/doSecureKeyLogin?uuid=d8594a82-ce8d-4e6c-8a1f-0da062c12f34&dateTime=201906240338&key=Y0T740bBERH2A2OfLiazdrjW%2FSBOVptff8I2XzU7I0M%3D&uri=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Fabs%2F10.1080%2F14740338.2019.1619693%3Fai%3D1pmh6%26ui%3D843fx%26af%3DT